Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

  1. Rosell, R.
  2. Carcereny, E.
  3. Gervais, R.
  4. Vergnenegre, A.
  5. Massuti, B.
  6. Felip, E.
  7. Palmero, R.
  8. Garcia-Gomez, R.
  9. Pallares, C.
  10. Sanchez, J.M.
  11. Porta, R.
  12. Cobo, M.
  13. Garrido, P.
  14. Longo, F.
  15. Moran, T.
  16. Insa, A.
  17. De Marinis, F.
  18. Corre, R.
  19. Bover, I.
  20. Illiano, A.
  21. Dansin, E.
  22. de Castro, J.
  23. Milella, M.
  24. Reguart, N.
  25. Altavilla, G.
  26. Jimenez, U.
  27. Provencio, M.
  28. Moreno, M.A.
  29. Terrasa, J.
  30. Muñoz-Langa, J.
  31. Valdivia, J.
  32. Isla, D.
  33. Domine, M.
  34. Molinier, O.
  35. Mazieres, J.
  36. Baize, N.
  37. Garcia-Campelo, R.
  38. Robinet, G.
  39. Rodriguez-Abreu, D.
  40. Lopez-Vivanco, G.
  41. Gebbia, V.
  42. Ferrera-Delgado, L.
  43. Bombaron, P.
  44. Bernabe, R.
  45. Bearz, A.
  46. Artal, A.
  47. Cortesi, E.
  48. Rolfo, C.
  49. Sanchez-Ronco, M.
  50. Drozdowskyj, A.
  51. Queralt, C.
  52. de Aguirre, I.
  53. Ramirez, J.L.
  54. Sanchez, J.J.
  55. Molina, M.A.
  56. Taron, M.
  57. Paz-Ares, L.
  58. Show all authors +
Journal:
The Lancet Oncology

ISSN: 1470-2045 1474-5488

Year of publication: 2012

Volume: 13

Issue: 3

Pages: 239-246

Type: Article

DOI: 10.1016/S1470-2045(11)70393-X GOOGLE SCHOLAR

Sustainable development goals